Dexcom (DXCM) Gross Margin (2010 - 2026)

Dexcom (DXCM) has 17 years of Gross Margin data on file, last reported at 62.95% in Q1 2026.

• On a quarterly basis, Gross Margin rose 610.0% year-over-year to 62.95% in Q1 2026; TTM through Mar 2026 was 61.5%, a 207.0% increase from a year earlier, with the FY2025 full-year figure at 60.1%, down 36.0% from the prior year.
• Gross Margin for Q1 2026 stood at 62.95%, roughly flat from 62.93% in the prior quarter.
• Over the last five years, Gross Margin for DXCM reached as high as 66.4% in Q4 2022 and fell as low as 56.85% in Q1 2025.
• Historically, Gross Margin has averaged 62.1% across 5 years, with a median of 62.71% in 2023.
• Across the five-year window, Gross Margin tumbled 552 bps in 2022 and surged 610 bps in 2026, its largest moves.
• Year by year, Gross Margin stood at 66.4% in 2022, then decreased by 4 bps to 63.47% in 2023, then dropped by 7 bps to 58.9% in 2024, then climbed by 7 bps to 62.93% in 2025, then rose by 0 bps to 62.95% in 2026.
• Per Business Quant data, the three most recent Gross Margin figures were 62.95% in Q1 2026, 62.93% in Q4 2025, and 60.48% in Q3 2025.